CHCWM – Cancer & Hematology Centers of West Michigan

TH1902-CTR-0001 (Theratechnologies, Inc.)

Description:  A Phase 1, Open-Label, Dose Escalation Study of TH1902 in Patients with Advanced Solid Tumors and Expansion in Patients with Triple Negative Breast Cancer (TNBC), Gynecological Cancer, Colorectal Cancer and Pancreatic Cancer

Mechanism of Action:  Peptide-drug conjugate that binds to SORT-1 with a docetaxel payload.

Target Patient Population:  Currently in Dose Escalation with all Solid Tumors. 

Study Design:  Drug is administered IV every 3 weeks.